Modi Ventures

Lila Sciences is a technology company that specializes in accelerating scientific research. It develops artificial intelligence-driven tools and autonomous labs, focusing on life sciences, chemical sciences, and materials sciences. The platform aims to enhance research efficiency and facilitate scientific discoveries by processing vast amounts of data, designing experiments, generating hypotheses, and testing them in real-world environments. This enables scientists to achieve breakthroughs and innovate more rapidly.

Ignota Labs is a pioneering medical technology company focused on enhancing the drug discovery process through advanced artificial intelligence methods. By utilizing deep learning and machine learning algorithms, the company aims to analyze complex molecular data to predict toxicity early in the development of pharmaceuticals. This proactive approach helps to identify harmful compounds, thereby minimizing environmental impact and waste. Ignota Labs' innovative platform not only streamlines the drug discovery process but also enhances drug safety, ultimately facilitating the timely introduction of life-changing medications to the market.

Innotap is a prominent provider of energy trading and commodity trading software, specializing in real-time decision support applications for power traders. The company offers a suite of innovative tools, including DecisionDock, InstaTrend, RealDeal Dashboards, and PowerFeed for Excel, which facilitate the monitoring of market conditions and help traders make informed decisions. By leveraging cloud-based technology and aggregating data from Independent System Operators (ISOs) and Regional Transmission Organizations (RTOs), Innotap enables energy traders to respond swiftly to market changes and seize profitable opportunities. With a focus on enhancing decision-making processes, Innotap combines data visualization and analytics, presenting users with a rich graphical interface that streamlines access to real-time market data.

Lapsi Health is a biotechnology company based in Amsterdam, Noord-Holland, established in January 2022. The company is dedicated to developing innovative biomarker technology that leverages sound as a diagnostic signal in clinical medicine. By focusing on the analysis of audio and photo-sensor data, Lapsi Health aims to enhance the healthcare sector's ability to screen and monitor a variety of disorders. Through its cutting-edge technology, the company seeks to improve data utilization in medicine, ultimately contributing to more effective disease management and treatment.

General Proximity Bio is an innovative biotech company focused on advancing proximity medicine. The company aims to develop next-generation drugs that utilize and activate existing cellular machinery to treat a range of harmful human diseases. By pioneering this approach, General Proximity Bio envisions a transformative future for medicine, enhancing treatment options and improving patient outcomes through targeted therapeutic strategies.

March Biosciences is a clinical-stage biotechnology company specializing in cell therapies for hematological cancers. It focuses on developing CAR-T cell therapies, with its lead product, MB-105, targeting CD5 in refractory T-cell lymphoma and leukemia. The company's approach involves biologically informed target selection, simplified CAR-T engineering, and a streamlined manufacturing process to ensure cell functionality and consistency.

Ozlo Sleep is a science-driven sleep and audio technology company that supports and simplifies sleep rituals for clinical benefits, without the use of medication.

PathPresenter is a global image-sharing platform designed specifically for the field of pathology. The company's mission is to democratize access to pathology knowledge by facilitating the sharing of image data, artificial intelligence algorithms, and specialized expertise among professionals. PathPresenter's platform offers a secure and HIPAA-compliant environment, allowing pathologists to collaborate more effectively with colleagues worldwide. This innovative approach aims to enhance the quality of care provided to patients by leveraging the collective knowledge and resources of the pathology community.

Latus Bio is a biotechnology company dedicated to developing innovative gene therapies for neurological diseases. It specializes in novel discovery approaches using non-human primate models, enabling precise delivery of therapeutic genes to targeted cells within the central nervous system. Latus Bio aims to enhance clinical safety and manufacturing efficiency by administering low doses of its proprietary adeno-associated virus (AAV) capsids.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.

Tiny Health is a prominent microbiome health platform focused on addressing chronic health conditions and optimizing overall well-being. The company offers innovative at-home microbiome testing kits, including the Gut Health Test specifically designed for pregnant mothers and their babies, as well as tests for older children and adults and Vaginal Health Tests. By utilizing shotgun metagenomics, Tiny Health provides families with personalized insights into their gut and vaginal microbiomes, allowing them to make informed dietary and lifestyle changes. To date, approximately 30,000 families have relied on Tiny Health's expertise to correct microbiome imbalances and enhance health outcomes, with many experiencing significant symptom reduction or even reversal of chronic conditions. The team at Tiny Health comprises leading scientists and medical professionals from prestigious institutions, ensuring a strong foundation in evidence-based health solutions.

Harbinger Health is a biotechnology company focused on the early detection of cancer through an innovative blood testing model. By integrating artificial intelligence and machine learning with biological insights, Harbinger Health aims to identify cancer at an early stage, even before symptoms become apparent. The company's approach is designed to facilitate low-cost, multi-cancer blood tests, which could significantly enhance diagnostic capabilities in healthcare. Through its advanced technology, Harbinger Health seeks to improve cancer outcomes by enabling timely intervention and diagnosis.

Unnatural Products Inc. is a biotechnology company based in Santa Cruz, California, focused on drug discovery through innovative technology. Founded in 2016, the company specializes in designing and developing a platform that utilizes artificial intelligence and computational biology techniques to create macrocyclic peptides. These peptides target intracellular protein interactions, addressing drug targets that are typically considered undruggable. By harnessing machine learning to optimize chemical synthesis, Unnatural Products aims to accelerate the drug discovery process, offering potential therapeutic strategies for a wide range of medical conditions. Through its unique approach, the company seeks to pioneer new treatments where traditional methods have fallen short.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Atomic AI is a company focused on advancing drug discovery through the innovative integration of machine learning and structural biology, specifically targeting RNA. The firm operates a content intelligence platform that facilitates the rational design of new molecules and medicines using artificial intelligence. By leveraging engagement data from clients' analytics, Atomic AI gathers valuable insights and generates predictive reports regarding relevant topics, optimal publishing times, and effective distribution channels. This approach equips users with strategies to develop therapies aimed at treating or curing diseases through the manipulation of RNA structures.

Perceptive is a company focused on the design, development, and manufacturing of advanced medical devices specifically for the dentistry industry. It specializes in automated robotics technology that aims to revolutionize dental care by making image-guided robotic restorative dentistry a standard practice. The company's innovative technology enhances the precision of dental procedures, allowing dentists to more accurately identify and remove tooth decay, ultimately leading to superior restorations for patients. By improving the efficiency of dental care, Perceptive enables practitioners to deliver high-quality services at a lower cost and in a reduced timeframe, thereby increasing clinical capacity and advancing the standard of care in dentistry.

Flawless is a technology company focused on revolutionizing the dubbing process in filmmaking through its innovative platform, TrueSync. This system employs artificial intelligence to create highly accurate lip-sync visualizations across multiple languages, ensuring that the emotional nuances and performance of the original actors are preserved. By enhancing mouth movements to align with the native language dialogue, Flawless addresses the shortcomings of traditional dubbing and subtitling, which often compromise content quality and audience engagement. The company’s approach not only improves the viewing experience but also significantly expands the potential audience for films and shows, thereby increasing their overall value in the global market.

Ashvattha Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapeutics that address unmet medical needs in neurology, oncology, ophthalmology, and inflammation. Founded in 2015 and headquartered in Redwood City, California, with research facilities in Baltimore, Maryland, the company specializes in hydroxyl dendrimer therapeutics. These products are designed to selectively target and treat diseases by engaging actively endocytosing cells such as reactive microglia and macrophages, which play a critical role in chronic inflammation and disease progression. By utilizing this precision targeting approach, Ashvattha Therapeutics aims to minimize off-target toxicity, systemic side effects, and immunogenicity often associated with conventional treatments, thereby enhancing treatment efficacy and patient outcomes. The company has a robust pipeline containing nine therapeutics across its areas of focus.

Lapsi Health is a biotechnology company based in Amsterdam, Noord-Holland, established in January 2022. The company is dedicated to developing innovative biomarker technology that leverages sound as a diagnostic signal in clinical medicine. By focusing on the analysis of audio and photo-sensor data, Lapsi Health aims to enhance the healthcare sector's ability to screen and monitor a variety of disorders. Through its cutting-edge technology, the company seeks to improve data utilization in medicine, ultimately contributing to more effective disease management and treatment.

Starling Medical is focused on creating a remote patient monitoring platform that facilitates at-home urine diagnostics, aiming to integrate seamlessly into everyday bathroom routines. The company designs healthcare devices that utilize mass spectroscopy-based sensors for continuous monitoring and early detection of health issues through urine analysis. By tracking changes in urine composition over time, Starling Medical's technology enables timely intervention for patients and healthcare providers, potentially preventing complications and reducing the need for hospitalizations. The organization is dedicated to developing predictive technology that enhances early detection of chronic health concerns, ultimately improving patient outcomes.